On August 26, according to BIT (bit.com) market data, biopharmaceutical stocks are experiencing speculation, with US-based Moderna (MRNA) closing up 14.36% and a trading volume reaching $7.636 billion. Merck (MRK) also saw a rise of 3.84%. Recently, Moderna and Merck jointly announced the successful results of their first personalized mRNA cancer therapy, intismeran autogene, in a global Phase III clinical trial targeting high-risk melanoma, marking a milestone breakthrough in the field of tumor immunotherapy. Several major banks have raised their target prices for Moderna; Bank of America increased its target price from $40 to $170, upgrading its rating to 'Neutral'; Piper Sandler raised its target price from $77 to $167, maintaining an 'Overweight' rating; Goldman Sachs increased its target price from $67 to $120, keeping a 'Neutral' rating; and JPMorgan raised its target price from $40 to $77, while Barclays increased its target price from $48 to $125. According to Bitget market data, after the Hong Kong stock market opened today, CanSino Biologics surged over 17%, Innovent Biologics rose over 10%, Genting Biologics increased over 7%, Kintor Pharmaceutical was up over 6%, and Rongchang Biologics rose over 4%. CanSino Biologics announced that its subsidiary, CanSino Shanghai, has officially signed a strategic cooperation framework agreement with DepoMed to jointly promote the research and commercialization of mRNA personalized therapeutic tumor vaccines.